This recombinant monoclonal antibody is designed as a research-grade biosimilar to the reference antibody described in US10865247B2, targeting CD69, a C-type lectin receptor expressed on activated lymphocytes. CD69 functions as an early activation marker on T cells, B cells, NK cells, and other leukocyte populations, playing critical roles in immune cell retention, differentiation, and effector functions. This transmembrane protein regulates lymphocyte egress from lymphoid tissues through sphingosine-1-phosphate receptor modulation and participates in inflammatory responses. CD69 expression is associated with various pathological conditions including autoimmune diseases, allergic disorders, inflammatory bowel disease, and tumor-infiltrating lymphocyte populations in cancer microenvironments.
The reference antibody serves as a benchmark for developing high-quality research reagents that maintain comparable binding characteristics and specificity. This biosimilar antibody provides researchers with a reliable tool for investigating CD69-mediated immune regulation, studying lymphocyte activation dynamics, exploring therapeutic targeting strategies in autoimmune conditions, and characterizing immune cell phenotypes in disease models and clinical samples.
Email: support@cusabio.com
Distributors Worldwide